Literature DB >> 24992165

Treatment of 4T1 metastatic breast cancer with combined hypofractionated irradiation and autologous T-cell infusion.

Alexander Filatenkov1, Jeanette Baker, Antonia M Müller, G-One Ahn, Holbrook Kohrt, Suparna Dutt, Kent Jensen, Sussan Dejbakhsh-Jones, Robert S Negrin, Judith A Shizuru, Edgar G Engleman, Samuel Strober.   

Abstract

The goal of this study was to determine whether a combination of local tumor irradiation and autologous T-cell transplantation can effectively treat metastatic 4T1 breast cancer in mice. BALB/c mice were injected subcutaneously with luciferase-labeled 4T1 breast tumor cells and allowed to grow for 21 days, at which time metastases appeared in the lungs. Primary tumors were treated at that time with 3 daily fractions of 20 Gy of radiation each. Although this approach could eradicate primary tumors, tumors in the lungs grew progressively. We attempted to improve efficacy of the radiation by adding autologous T-cell infusions. Accordingly, T cells were purified from the spleens of tumor-bearing mice after completion of irradiation and cryopreserved. Cyclophosphamide was administered thereafter to induce lymphodepletion, followed by T-cell infusion. Although the addition of cyclophosphamide to irradiation did not improve survival or reduce tumor progression, the combination of radiation, cyclophosphamide and autologous T-cell infusion induced durable remissions and markedly improved survival. We conclude that the combination of radiation and autologous T-cell infusion is an effective treatment for metastatic 4T1 breast cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24992165      PMCID: PMC4137907          DOI: 10.1667/RR13471.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  38 in total

Review 1.  New insights on cell death from radiation exposure.

Authors:  Kevin M Prise; Giuseppe Schettino; Melvyn Folkard; Kathryn D Held
Journal:  Lancet Oncol       Date:  2005-07       Impact factor: 41.316

2.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

Authors:  Mark E Dudley; John R Wunderlich; James C Yang; Richard M Sherry; Suzanne L Topalian; Nicholas P Restifo; Richard E Royal; Udai Kammula; Don E White; Sharon A Mavroukakis; Linda J Rogers; Gerald J Gracia; Stephanie A Jones; David P Mangiameli; Michelle M Pelletier; Juan Gea-Banacloche; Michael R Robinson; David M Berman; Armando C Filie; Andrea Abati; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

Review 3.  Combining radiotherapy and immunotherapy: a revived partnership.

Authors:  Sandra Demaria; Nina Bhardwaj; William H McBride; Silvia C Formenti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-11-01       Impact factor: 7.038

4.  Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy.

Authors:  Kathryn A Mason; Hisanori Ariga; Robert Neal; David Valdecanas; Nancy Hunter; Arthur M Krieg; John K Whisnant; Luka Milas
Journal:  Clin Cancer Res       Date:  2005-01-01       Impact factor: 12.531

5.  Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.

Authors:  Amit A Lugade; James P Moran; Scott A Gerber; Robert C Rose; John G Frelinger; Edith M Lord
Journal:  J Immunol       Date:  2005-06-15       Impact factor: 5.422

6.  Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells.

Authors:  Shao-An Xue; Liquan Gao; Daniel Hart; Roopinder Gillmore; Waseem Qasim; Adrian Thrasher; Jane Apperley; Boris Engels; Wolfgang Uckert; Emma Morris; Hans Stauss
Journal:  Blood       Date:  2005-07-14       Impact factor: 22.113

7.  Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.

Authors:  Sandra Demaria; Noriko Kawashima; Anne Marie Yang; Mary Louise Devitt; James S Babb; James P Allison; Silvia C Formenti
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

Review 8.  The DNA damage response arouses the immune system.

Authors:  Stephan Gasser; David H Raulet
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

9.  CpG oligodeoxynucleotide enhances tumor response to radiation.

Authors:  Luka Milas; Kathryn A Mason; Hisanori Ariga; Nancy Hunter; Robert Neal; David Valdecanas; Arthur M Krieg; John K Whisnant
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

10.  Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells.

Authors:  Yu-Pei Liao; Chun-Chieh Wang; Lisa H Butterfield; James S Economou; Antoni Ribas; Wilson S Meng; Keisuke S Iwamoto; William H McBride
Journal:  J Immunol       Date:  2004-08-15       Impact factor: 5.422

View more
  9 in total

Review 1.  Strategies for combining immunotherapy with radiation for anticancer therapy.

Authors:  Steven N Seyedin; Jonathan E Schoenhals; Dean A Lee; Maria A Cortez; Xiaohong Wang; Sharareh Niknam; Chad Tang; David S Hong; Aung Naing; Padmanee Sharma; James P Allison; Joe Y Chang; Daniel R Gomez; John V Heymach; Ritsuko U Komaki; Laurence J Cooper; James W Welsh
Journal:  Immunotherapy       Date:  2015-08-27       Impact factor: 4.196

2.  Irradiation enhances dendritic cell potential antitumor activity by inducing tumor cell expressing TNF-α.

Authors:  Lijia Chang; Zhengzheng Zhang; Fang Chen; Wen Zhang; Shuang Song; Shuxia Song
Journal:  Med Oncol       Date:  2017-02-13       Impact factor: 3.064

Review 3.  The Future of Combining Carbon-Ion Radiotherapy with Immunotherapy: Evidence and Progress in Mouse Models.

Authors:  Takashi Shimokawa; Liqiu Ma; Ken Ando; Katsutoshi Sato; Takashi Imai
Journal:  Int J Part Ther       Date:  2016-08-29

Review 4.  Radiation therapy and immunotherapy: what is the optimal timing or sequencing?

Authors:  Maureen L Aliru; Jonathan E Schoenhals; Bhanu P Venkatesulu; Clark C Anderson; Hampartsoum B Barsoumian; Ahmed I Younes; Lakshmi S K Mahadevan; Melinda Soeung; Kathryn E Aziz; James W Welsh; Sunil Krishnan
Journal:  Immunotherapy       Date:  2018-02-01       Impact factor: 4.196

5.  Iron oxide nanoparticle targeted chemo-immunotherapy for triple negative breast cancer.

Authors:  Qin Gxin Mu; Guanyou Lin; Mike Jeon; Hui Wang; Fei-Chien Chang; Richard A Revia; John Yu; Miqin Zhang
Journal:  Mater Today (Kidlington)       Date:  2021-09-07       Impact factor: 31.041

6.  Immunobiology of radiotherapy: new paradigms.

Authors:  Mansoor M Ahmed; Chandan Guha; James W Hodge; Elizabeth Jaffee
Journal:  Radiat Res       Date:  2014-07-18       Impact factor: 2.841

Review 7.  Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review.

Authors:  Franziska Hauth; Alice Y Ho; Soldano Ferrone; Dan G Duda
Journal:  JAMA Oncol       Date:  2021-07-01       Impact factor: 33.006

Review 8.  Radiation-induced immune responses: mechanisms and therapeutic perspectives.

Authors:  Hoibin Jeong; Seoyeon Bok; Beom-Ju Hong; Hyung-Seok Choi; G-One Ahn
Journal:  Blood Res       Date:  2016-09-23

9.  177Lu-NM600 Targeted Radionuclide Therapy Extends Survival in Syngeneic Murine Models of Triple-Negative Breast Cancer.

Authors:  Reinier Hernandez; Joseph J Grudzinski; Eduardo Aluicio-Sarduy; Christopher F Massey; Anatoly N Pinchuk; Ariana N Bitton; Ravi Patel; Ray Zhang; Aakarsha V Rao; Gopal Iyer; Jonathan W Engle; Jamey P Weichert
Journal:  J Nucl Med       Date:  2019-12-20       Impact factor: 10.057

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.